Maravai LifeSciences (MRVI) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Maravai LifeSciences (MRVI) over the past year, gaining 127.8% versus a gain of 124.5%. Over five years, PGEN leads with a +62.2% price change compared with -80.0% for MRVI. Precigen is the larger company by market cap ($2.72 billion vs $2.67 billion), about 1.0 times the size.
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | PGEN |
|---|---|---|
| Share price | $7.21 | $7.60 |
| Market cap | $2.67B | $2.72B |
| 1-day change | -2.96% | +0.80% |
| YTD return | +128.62% | +80.38% |
| 1-year return | +124.47% | +127.79% |
| 5-year return | -79.97% | +62.15% |
| EPS (TTM) | $-0.53 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $9.68M |
| Revenue growth (YoY) | -28.34% | +146.73% |
| Net income (latest FY) | $-130.77M | $-250.64M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -1141.13% |
| Net margin | -70.41% | -2588.21% |
| 52-week high | $9.42 | $8.98 |
| 52-week low | $2.55 | $2.99 |
| Distance from 52-week high | -23.46% | -15.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +8.60% | +79.61% |
| Average volume | 3.33M | 5.02M |
| Shares outstanding | 148.99M | 358.04M |
| Employees | 415 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
MRVI vs PGEN FAQ
Which is bigger, Maravai LifeSciences or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $2.67B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, MRVI or PGEN?
PGEN returned +127.79% over the past 12 months, compared with +124.47% for MRVI (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.